Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Consumer Eli Lilly & Organon Partner to Distribute Migraine Treatment Throughout Europe

Eli Lilly & Organon Partner to Distribute Migraine Treatment Throughout Europe

20th December 2023

Organon and Eli Lilly and Company have reached a distribution deal to sell two migraine treatments, Emgality and REYVOW, in European countries. 

The business is set to obtain an initial payment of $50 million, along with additional performance-based payments in relation to treatment sales. 

Emgality is a treatment used to help prevent migraines in adults who experience at least 4 migraine days per month. It works by blocking a substance in the body called calcitonin gene-related peptides. 

REYVOW works by targeting a specific receptor in the brain called serotonin 5-HT1F, and it can be used during the headache stage of migraine episodes, regardless of whether there are visual disturbances (aura). 

Kevin Ali, the head executive of Organon, commented, “This commercialisation agreement aligns seamlessly with Organon’s suite of central nervous system treatments in our established brands portfolio and, most importantly, it further bolsters our offerings to women, who are disproportionately impacted by migraine.” 

Ali went on to add, “Our strong commercial expertise and proven track record in this therapeutic area will help enable us to bring these important treatments to more patients across Europe who need them.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved. 

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.